Evoke Pharma Q3 EPS $(0.51) Beats $(0.62) Estimate, Sales $1.56M Beat $1.26M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma reported Q3 losses of $(0.51) per share, beating the analyst consensus estimate of $(0.62) by 17.74%. This is a 15% increase over losses from the same period last year. The company also reported quarterly sales of $1.56 million, beating the analyst consensus estimate of $1.26 million by 24.05%. This is an 87.84% increase over sales from the same period last year.
November 09, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evoke Pharma's Q3 results beat estimates, with losses less than expected and sales higher than expected.
Evoke Pharma's Q3 results exceeded analyst expectations, which could lead to a positive market reaction. The company's losses were less than expected and sales were higher than expected, indicating improved financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100